Non-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo. GPR55 and weak CB1 antagonist (IC50 values are 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50 = 27.5 μM). Also a weak agonist at VR1 vanilloid receptors (EC50 = 3.5 μM).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 314.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.75 mM||4.24 mL||21.2 mL||42.4 mL|
|3.75 mM||0.85 mL||4.24 mL||8.48 mL|
|7.5 mM||0.42 mL||2.12 mL||4.24 mL|
|37.5 mM||0.08 mL||0.42 mL||0.85 mL|
References are publications that support the biological activity of the product.
Costa et al (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br.J.Pharmacol. 143 247 PMID: 15313881
Petitet et al (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63 PL1 PMID: 9667767
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092 PMID: 17876302
Thomas et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br.J.Pharmacol. 150 613 PMID: 17245363
If you know of a relevant reference for (-)-Cannabidiol, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (-)-Cannabidiol, (-)-Cannabidiol supplier, Natural, cannabinoids, AMT, inhibitors, inhibits, GPR55, antagonists, weak, CB1, CB2, inverse, agonists, Anandamide, Transporters, Monoamine, Neurotransmitter, Non-Selective, Receptors, cb2r, cb1r, CBD, Cannabinoid, Non-selective, Cannabinoids, 1570, Tocris Bioscience
3 Citations for (-)-Cannabidiol
Citations are publications that use Tocris products. Selected citations for (-)-Cannabidiol include:
Esposito et al (2011) Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. Proc Natl Acad Sci U S A 6 e28668 PMID: 22163051
Hamtiaux et al (2011) Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One 6 e26823 PMID: 22046372
Whyte et al (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. PLoS One 106 16511 PMID: 19805329
Do you know of a great paper that uses (-)-Cannabidiol from Tocris? Please let us know.
Reviews for (-)-Cannabidiol
There are currently no reviews for this product. Be the first to review (-)-Cannabidiol and earn rewards!
Have you used (-)-Cannabidiol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.